{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:40:23Z","timestamp":1789094423647,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The rise in antifungal resistance has limited treatment options for serious fungal infections, emphasizing the need for effective combination therapies. However, low-cost and rapid systems to evaluate synergy and antagonism in antifungal combinations are lacking. Here, we introduce a novel in vitro testing method for assessing antifungal interactions in C. <jats:italic>albicans<\/jats:italic>, enabling the simultaneous testing of three antifungal agents in a single agar plate with overnight results. This method, validated against the checkerboard assay, provides consistent fractional inhibitory concentration (FICi) measurements with reduced variability and workload. We applied this method in a comprehensive screen of 92 clinical C. <jats:italic>albicans<\/jats:italic> isolates for three antifungals\u2014amphotericin B, fluconazole, and anidulafungin\u2014yielding assessments of a total of 276 distinct combinations of antifungals and isolates. Results revealed isolate-specific interaction patterns, with amphotericin B and fluconazole showing synergy in 1% of isolates, anidulafungin and fluconazole in 19.5%, and amphotericin B and anidulafungin in 23.9%. These findings underscore the need for isolate-specific testing in clinical settings. This proposed assay aims to present a solution to that as a scalable high throughput approach to this clinical problem.<\/jats:p>","DOI":"10.1038\/s41598-025-22870-x","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:04:36Z","timestamp":1760540676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fast detection of synergy and antagonism in antifungal combinations used against Candida albicans clinical isolates"],"prefix":"10.1038","volume":"15","author":[{"given":"Hanna","family":"Lundvik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugce Unalan","family":"Altintop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"\u00d6zenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan I.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Fatsis-Kavalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"12","key":"22870_CR1","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","volume":"17","author":"DS Perlin","year":"2017","unstructured":"Perlin, D. S., Rautemaa-Richardson, R. & Alastruey-Izquierdo, A. The global problem of antifungal resistance: Prevalence, mechanisms, and management. Lancet Infect. Dis. 17(12), e383\u2013e392 (2017).","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"22870_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11908-019-0702-9","volume":"21","author":"JA Hendrickson","year":"2019","unstructured":"Hendrickson, J. A., Hu, C., Aitken, S. L. & Beyda, N. Antifungal resistance: A concerning trend for the present and future. Curr. Infect. Dis. Rep. 21(12), 47 (2019).","journal-title":"Curr. Infect. Dis. Rep."},{"issue":"4","key":"22870_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2012.10.003","volume":"74","author":"M Pfaller","year":"2012","unstructured":"Pfaller, M. et al. Epidemiology and outcomes of candidemia in 3648 patients: Data from the prospective antifungal therapy (PATH Alliance\u00ae) registry, 2004\u20132008. Diagn. Microbiol. Infect. Dis. 74(4), 323\u2013331 (2012).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"issue":"3","key":"22870_CR4","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001318","volume":"70","author":"A Chakrabarti","year":"2021","unstructured":"Chakrabarti, A. & Sood, P. On the emergence, spread and resistance of Candida auris: Host, pathogen and environmental tipping points. J. Med. Microbiol. 70(3), 001318 (2021).","journal-title":"J. Med. Microbiol."},{"issue":"6","key":"22870_CR5","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/S2666-5247(23)00067-8","volume":"4","author":"F Daneshnia","year":"2023","unstructured":"Daneshnia, F. et al. Worldwide emergence of fluconazole-resistant Candida parapsilosis: Current framework and future research roadmap. Lancet Microbe 4(6), e470\u2013e480 (2023).","journal-title":"Lancet Microbe"},{"issue":"5","key":"22870_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.apjtb.2015.12.019","volume":"6","author":"R Kaur","year":"2016","unstructured":"Kaur, R., Dhakad, M. S., Goyal, R. & Kumar, R. Emergence of non-albicans Candida species and antifungal resistance in intensive care unit patients. Asian Pac. J. Trop. Biomed. 6(5), 455\u2013460 (2016).","journal-title":"Asian Pac. J. Trop. Biomed."},{"issue":"10","key":"22870_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/jof8101077","volume":"8","author":"S Fioriti","year":"2022","unstructured":"Fioriti, S. et al. Antifungal combinations against candida species: From bench to bedside. J. Fungi 8(10), 1077 (2022).","journal-title":"J. Fungi"},{"issue":"3","key":"22870_CR8","doi-asserted-by":"publisher","first-page":"e13066","DOI":"10.1111\/tid.13066","volume":"21","author":"KY Qiu","year":"2019","unstructured":"Qiu, K. Y. et al. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders. Transpl. Infect. Dis. 21(3), e13066 (2019).","journal-title":"Transpl. Infect. Dis."},{"issue":"1","key":"22870_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1155\/2014\/308169","volume":"25","author":"S Haider","year":"2014","unstructured":"Haider, S., Rotstein, C., Horn, D., Laverdiere, M. & Azie, N. The Prospective antifungal therapy alliance\u00ae registry: A two-centre Canadian experience. Can. J. Infect. Dis. Med. Microbiol. 25(1), 17 (2014).","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"issue":"6","key":"22870_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.14740\/jocmr2992w","volume":"9","author":"M Campitelli","year":"2017","unstructured":"Campitelli, M., Zeineddine, N., Samaha, G. & Maslak, S. Combination antifungal therapy: A review of current data. J. Clin. Med. Res. 9(6), 451 (2017).","journal-title":"J. Clin. Med. Res."},{"issue":"4","key":"22870_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas, P. G. et al. Clinical Practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. 62(4), e1-50 (2016).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"22870_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12281-010-0018-6","volume":"4","author":"MD Johnson","year":"2010","unstructured":"Johnson, M. D. & Perfect, J. R. Use of antifungal combination therapy: Agents, order, and timing. Curr. Fungal Infect. Rep. 4(2), 87 (2010).","journal-title":"Curr. Fungal Infect. Rep."},{"issue":"1","key":"22870_CR13","doi-asserted-by":"publisher","first-page":"17070","DOI":"10.1038\/srep17070","volume":"5","author":"SK Shrestha","year":"2015","unstructured":"Shrestha, S. K., Fosso, M. Y. & Garneau-Tsodikova, S. A combination approach to treating fungal infections. Sci. Rep. 5(1), 17070 (2015).","journal-title":"Sci. Rep."},{"key":"22870_CR14","volume-title":"Antifungal Antibiotics","author":"PT McKeny","year":"2024","unstructured":"McKeny, P. T., Nessel, T. A. & Zito, P. M. Antifungal Antibiotics (StatPearls, 2024)."},{"issue":"1","key":"22870_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/lam.12820","volume":"66","author":"AM Fuentefria","year":"2018","unstructured":"Fuentefria, A. M., Pippi, B., Dalla Lana, D. F., Donato, K. K. & de Andrade, S. F. Antifungals discovery: An insight into new strategies to combat antifungal resistance. Lett. Appl. Microbiol. 66(1), 2\u201313 (2018).","journal-title":"Lett. Appl. Microbiol."},{"issue":"6","key":"22870_CR16","volume":"1","author":"LW El Ayoubi","year":"2024","unstructured":"El Ayoubi, L. W., Allaw, F., Moussa, E. & Kanj, S. S. Ibrexafungerp: A narrative overview. Curr. Res. Microb. Sci. 1(6), 100245 (2024).","journal-title":"Curr. Res. Microb. Sci."},{"issue":"6","key":"22870_CR17","doi-asserted-by":"publisher","first-page":"ofae072","DOI":"10.1093\/ofid\/ofae072","volume":"11","author":"RM Wake","year":"2024","unstructured":"Wake, R. M. et al. Optimizing the treatment of invasive candidiasis\u2014A case for combination therapy. Open Forum Infect. Dis. 11(6), ofae072 (2024).","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"22870_CR18","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S2666-5247(20)30090-2","volume":"1","author":"B O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, B., Liang, J., Chaturvedi, S., Jacobs, J. L. & Chaturvedi, V. Pan-resistant Candida auris: New York subcluster susceptible to antifungal combinations. Lancet Microbe 1(5), e193\u2013e194 (2020).","journal-title":"Lancet Microbe"},{"issue":"7","key":"22870_CR19","doi-asserted-by":"publisher","first-page":"e00053","DOI":"10.1128\/aac.00053-22","volume":"66","author":"SE Jacobs","year":"2022","unstructured":"Jacobs, S. E. et al. Candida auris pan-drug-resistant to four classes of antifungal agents. Antimicrob. Agents Chemother. 66(7), e00053-e122 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22870_CR20","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02195-19","author":"B O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, B., Chaturvedi, S. & Chaturvedi, V. In vitro evaluation of antifungal drug combinations against multidrug-resistant candida auris isolates from New York outbreak. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02195-19 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22870_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/ffunb.2021.683414\/full","author":"H Gaikani","year":"2021","unstructured":"Gaikani, H., Smith, A. M., Lee, A. Y., Giaever, G. & Nislow, C. Systematic prediction of antifungal drug synergy by chemogenomic screening in saccharomyces cerevisiae. Front. Fungal. Biol. https:\/\/doi.org\/10.3389\/ffunb.2021.683414\/full (2021).","journal-title":"Front. Fungal. Biol."},{"issue":"1","key":"22870_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/msb.2009.95","volume":"5","author":"G Jansen","year":"2009","unstructured":"Jansen, G. et al. Chemogenomic profiling predicts antifungal synergies. Mol. Syst. Biol. 5(1), 338 (2009).","journal-title":"Mol. Syst. Biol."},{"key":"22870_CR23","doi-asserted-by":"publisher","first-page":"e54160","DOI":"10.7554\/eLife.54160","volume":"9","author":"MA Wambaugh","year":"2020","unstructured":"Wambaugh, M. A. et al. Synergistic and antagonistic drug interactions in the treatment of systemic fungal infections. Elife 9, e54160 (2020).","journal-title":"Elife"},{"issue":"4","key":"22870_CR24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1128\/AAC.01510-09","volume":"55","author":"V Chaturvedi","year":"2011","unstructured":"Chaturvedi, V. et al. Multilaboratory Testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob. Agents Chemother. 55(4), 1543 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"22870_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/jof7020113","volume":"7","author":"AL Bidaud","year":"2021","unstructured":"Bidaud, A. L., Schwarz, P., Herbreteau, G. & Dannaoui, E. Techniques for the assessment of in vitro and in vivo antifungal combinations. J Fungi. 7(2), 113 (2021).","journal-title":"J Fungi."},{"issue":"9","key":"22870_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000856","volume":"18","author":"N Fatsis-Kavalopoulos","year":"2020","unstructured":"Fatsis-Kavalopoulos, N., Roemhild, R., Tang, P. C., Kreuger, J. & Andersson, D. I. CombiANT: Antibiotic interaction testing made easy. PLOS Biol. 18(9), e3000856 (2020).","journal-title":"PLOS Biol."},{"issue":"16","key":"22870_CR27","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1039\/C9LC00585D","volume":"19","author":"WB Lee","year":"2019","unstructured":"Lee, W. B. et al. An integrated microfluidic system for antimicrobial susceptibility testing with antibiotic combination. Lab Chip 19(16), 2699\u20132708 (2019).","journal-title":"Lab Chip"},{"issue":"4","key":"22870_CR28","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.apsb.2023.11.027","volume":"14","author":"F Shao","year":"2024","unstructured":"Shao, F. et al. Automated and miniaturized screening of antibiotic combinations via robotic-printed combinatorial droplet platform. Acta Pharm. Sin. B 14(4), 1801\u20131813 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"22870_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41564-023-01486-9","volume":"8","author":"E Cacace","year":"2023","unstructured":"Cacace, E. et al. Systematic analysis of drug combinations against Gram-positive bacteria. Nat Microbiol. 8, 1\u201317 (2023).","journal-title":"Nat Microbiol."},{"key":"22870_CR30","doi-asserted-by":"publisher","first-page":"103979","DOI":"10.1016\/j.ebiom.2022.103979","volume":"78","author":"N Fatsis-Kavalopoulos","year":"2022","unstructured":"Fatsis-Kavalopoulos, N., Roelofs, L. & Andersson, D. I. Potential risks of treating bacterial infections with a combination of \u03b2-lactam and aminoglycoside antibiotics: A systematic quantification of antibiotic interactions in E. coli blood stream infection isolates. EBioMedicine 78, 103979 (2022).","journal-title":"EBioMedicine"},{"issue":"3","key":"22870_CR31","doi-asserted-by":"publisher","first-page":"e0019624","DOI":"10.1128\/mbio.00196-24","volume":"15","author":"PC Tang","year":"2024","unstructured":"Tang, P. C., S\u00e1nchez-Hevia, D. L., Westhoff, S., Fatsis-Kavalopoulos, N. & Andersson, D. I. Within-species variability of antibiotic interactions in Gram-negative bacteria. MBio 15(3), e0019624 (2024).","journal-title":"MBio"},{"issue":"9","key":"22870_CR32","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1093\/jac\/dkae233","volume":"79","author":"N Fatsis-Kavalopoulos","year":"2024","unstructured":"Fatsis-Kavalopoulos, N., S\u00e1nchez-Hevia, D. L. & Andersson, D. I. Beyond the FIC index: The extended information from fractional inhibitory concentrations (FICs). J. Antimicrob. Chemother. 79(9), 2394\u20132396 (2024).","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"22870_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/jac\/11.5.427","volume":"11","author":"MJ Hall","year":"1983","unstructured":"Hall, M. J., Middleton, R. F. & Westmacott, D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J. Antimicrob. Chemother. 11(5), 427\u2013433 (1983).","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"22870_CR34","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3(6), 285\u2013290 (1953).","journal-title":"Arzneimittelforschung"},{"issue":"2","key":"22870_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis, J., Pournaras, S., Roilides, E. & Walsh, T. J. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54(2), 602\u2013609 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"22870_CR36","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1128\/AAC.46.9.2982-2989.2002","volume":"46","author":"DTA Te Dorsthorst","year":"2002","unstructured":"Te Dorsthorst, D. T. A. et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46(9), 2982\u20132989 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"22870_CR37","doi-asserted-by":"publisher","first-page":"e00270","DOI":"10.1128\/AAC.00270-18","volume":"62","author":"S Deng","year":"2018","unstructured":"Deng, S. et al. Combination of amphotericin B and terbinafine against melanized fungi associated with chromoblastomycosis. Antimicrob. Agents Chemother. 62(6), e00270-e318 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"22870_CR38","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/AAC.44.9.2373-2381.2000","volume":"44","author":"O Marchetti","year":"2000","unstructured":"Marchetti, O., Moreillon, P., Glauser, M. P., Bille, J. & Sanglard, D. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44(9), 2373\u20132381 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"22870_CR39","unstructured":"Guinea, J., Meletiadis, J., Arikan-Akdagli, S., Giske, C., Muehlethaler, K., Arendrup, M. C. and the, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for, et al. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts (EUCAST, 2023). https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Files\/EUCAST_E.Def_7.4_Yeast_definitive_revised_2023.pdf"},{"issue":"10","key":"22870_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/jof9100973","volume":"9","author":"R Vahedi-Shahandashti","year":"2023","unstructured":"Vahedi-Shahandashti, R., Stubenb\u00f6ck, M. M. & Lass-Fl\u00f6rl, C. The influence of medium composition on EUCAST and Etest antifungal susceptibility testing. J. Fungi 9(10), 973 (2023).","journal-title":"J. Fungi"},{"issue":"2","key":"22870_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jac\/dkp429","volume":"65","author":"S Tobudic","year":"2010","unstructured":"Tobudic, S., Kratzer, C., Lassnigg, A., Graninger, W. & Presterl, E. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65(2), 271\u2013274 (2010).","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"22870_CR42","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/mmy\/myab032","volume":"59","author":"F Nagy","year":"2021","unstructured":"Nagy, F. et al. In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms. Med. Mycol. 59(10), 1015 (2021).","journal-title":"Med. Mycol."},{"issue":"12","key":"22870_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01393-19","volume":"63","author":"AL Bidaud","year":"2019","unstructured":"Bidaud, A. L., Botterel, F., Chowdhary, A. & Dannaoui, E. In Vitro antifungal combination of flucytosine with Amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. Antimicrob Agents Chemother. 63(12), e01393 (2019).","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"22870_CR44","first-page":"859","volume":"55","author":"A Katragkou","year":"2017","unstructured":"Katragkou, A. et al. In vitro combination therapy with isavuconazole against Candida spp. Med Mycol. 55(8), 859\u2013868 (2017).","journal-title":"Med Mycol."},{"issue":"11","key":"22870_CR45","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/AAC.40.11.2511","volume":"40","author":"JA Vazquez","year":"1996","unstructured":"Vazquez, J. A., Arganoza, M. T., Vaishampayan, J. K. & Akins, R. A. In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob. Agents Chemother. 40(11), 2511 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"122","key":"22870_CR46","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ijid.2022.07.056","volume":"1","author":"Q Yang","year":"2022","unstructured":"Yang, Q. et al. In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against candida species determined by the Etest method. Int. J. Infect. Dis. 1(122), 982\u2013990 (2022).","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"22870_CR47","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1128\/AAC.42.6.1382","volume":"42","author":"RE Lewis","year":"1998","unstructured":"Lewis, R. E., Lund, B. C., Klepser, M. E., Ernst, E. J. & Pfaller, M. A. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42(6), 1382\u20131386 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"22870_CR48","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1086\/374850","volume":"36","author":"JH Rex","year":"2003","unstructured":"Rex, J. H. et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. 36(10), 1221\u20131228 (2003).","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"22870_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/jof9040434","volume":"9","author":"J Meletiadis","year":"2023","unstructured":"Meletiadis, J., Beredaki, M. I., Elefanti, A., Pournaras, S. & Muller, A. In vitro\u2013in vivo correlation of posaconazole\u2013amphotericin B combination against Candida albicans: In vitro interacting concentrations are associated with in vivo free drug levels. J. Fungi 9(4), 434 (2023).","journal-title":"J. Fungi"},{"issue":"4","key":"22870_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano, G. L. Antimicrobial pharmacodynamics: Critical interactions of \u201cbug and drug\u201d. Nat. Rev. Microbiol. 2(4), 289\u2013300 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"22870_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mib.2015.05.008","volume":"27","author":"T Bollenbach","year":"2015","unstructured":"Bollenbach, T. Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution. Curr. Opin. Microbiol. 27, 1\u20139 (2015).","journal-title":"Curr. Opin. Microbiol."},{"issue":"4","key":"22870_CR52","doi-asserted-by":"publisher","first-page":"O255","DOI":"10.1111\/1469-0691.12373","volume":"20","author":"E Matuschek","year":"2014","unstructured":"Matuschek, E., Brown, D. F. J. & Kahlmeter, G. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. 20(4), O255\u2013O266 (2014).","journal-title":"Clin. Microbiol. Infect."},{"key":"22870_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1385\/1-59259-943-5:143","volume-title":"Antifungal Agents: Methods and Protocols","author":"RG Vitale","year":"2005","unstructured":"Vitale, R. G., Afeltra, J. & Dannaoui, E. Antifungal Combinations. In Antifungal Agents: Methods and Protocols (eds Ernst, E. J. & Rogers, P. D.) 143\u2013152 (Humana Press, 2005). https:\/\/doi.org\/10.1385\/1-59259-943-5:143."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22870-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22870-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:03:12Z","timestamp":1760544192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22870-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22870"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22870-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declrations"}},{"value":"Authors NFK and DIA hold shares and have decision making capacity in Rx Dynamics AB. All the remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36103"}}